Emerging treatments, such as lerodalcibep (PSCK9i), plozasiran (APOC3 siRNA), pemafibrate (SPPARMα), and inclisiran (PCSK9i), show promising results in reducing LDL-C and TG levels while minimizing the side effects and maintaining or even increasing the levels of efficacy in combination therapy. Lerodalcibep is a promising dyslipidemia therapy candidate with versatility in managing patients with HoFH, HeFH, and ASCVD. Here, APOC3 is linked to metabolic syndrome.